BiotechTube

ABT-335 + Rosuvastatin

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemia, Renal Insufficiency

Conditions

Dyslipidemia, Renal Insufficiency

Trial Timeline

Jan 1, 2008 → Oct 1, 2008

NCT ID
NCT00585143

About ABT-335 + Rosuvastatin

ABT-335 + Rosuvastatin is a phase 1 stage product being developed by AstraZeneca for Dyslipidemia, Renal Insufficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00585143. Target conditions include Dyslipidemia, Renal Insufficiency.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00585143Phase 1Completed

Competing Products

20 competing products in Dyslipidemia, Renal Insufficiency

See all competitors
ProductCompanyStageHype Score
LY3202328 + Placebo + Atorvastatin + SimvastatinEli LillyPhase 1
33
Pitavastatin + PravastatinEli LillyApproved
85
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
85
YH14755 + Metformin + RosuvastatinYuhanPhase 3
77
YHR1705 + YHR1706 + YHR1705+YHR1706YuhanPhase 1
33
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
23
Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDCYuhanPhase 1
33
MevalotinDaiichi SankyoPre-clinical
23
PravastatinDaiichi SankyoPre-clinical
23
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SCEli LillyPhase 1
33
LY3885125 + PlaceboEli LillyPhase 1
33
LY3561774 + PlaceboEli LillyPhase 1
33
LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for StatinsEli LillyPhase 2
52
LY3561774 + PlaceboEli LillyPhase 2
52
LY2484595 + Placebo + AtorvastatinEli LillyPhase 2
52
EvacetrapibEli LillyPhase 1
33
PPAR alpha + placeboEli LillyPhase 2
52
AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + PlaceboAstraZenecaPhase 1
33
AZD6615 + PlaceboAstraZenecaPhase 1
33
AZD0780 + AZD0780 + AZD0780 + Placebo + Placebo + Placebo + RosuvastatinAstraZenecaPhase 1
33

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85